Collegium Pharmaceutical, Inc. · NASDAQ:COLL
Collegium Pharmaceutical — Q2 2025 Earnings Presentation
23 slides from Collegium Pharmaceutical's earnings presentation, Aug 7, 2025
Slide 1: Q2 2025 Earnings Report
Q2 2025 Earnings Report August 7, 2025 | Nasdaq: COLL Healthier people. Stronger communities.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates,"
Slide 3: Business Update
Business Update Vikram Karnani President & Chief Executive Officer
Slide 4: Collegium is Well-Positioned for Continued Growth
4 Building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions Healthier people. Stronger communities. Collegium is Well-Positioned for Continued Growth 1. This financial data is calculated based on data provided by Colle
Slide 5: Recent Business Highlights – Q2 2025
5 Recent Business Highlights – Q2 20251 1. Unless otherwise noted, this financial data was provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on August 7, 2025. 2. IQVIA NPA through June 2025. 3. Represents a non-GAAP financial measure. Refer
Slide 6: Building on a Successful Strategy
DRIVE SIGNIFICANT Jornay PM Growth • Invest in Jornay PM to support near-term growth and create significant momentum in 2026 and beyond • Increase adoption in an expanded set of prescribers • Raise awareness in patients and caregivers to drive prescription growth 6 Building on a Successful Strategy
Slide 7: Collegium's Vision for the Next Phase of Growth
7 Collegium’s Vision for the Next Phase of Growth1 Time 1. Illustrative purposes only. Opportunity FUTURE FURTHER EXPANSION Product diversification and capital deployment NEUROPSYCHIATRY PAIN PORTFOLIO
Slide 8: Commercial Update
Commercial Update Scott Dreyer Executive Vice President & Chief Commercial Officer
Slide 9: Product Differentiation and Strong Brand Fundamentals Drive Utilization
Strong Intent to Increase Prescribing 9 Product Differentiation and Strong Brand Fundamentals Drive Utilization1 1. ATU (Awareness, Trial, & Usage) Market Research Study, completed Q2 2025. Jornay PM Considered Highly Differentiated #1 highest rated branded ADHD medicine in terms of product differen
Slide 10: Fastest Growing Stimulant for Treatment of ADHD
16% 23% Q2'24 Q2'25 10 Fastest Growing Stimulant for Treatment of ADHD STRONG AND GROWING PRESCRIBER BASE2 ACCELERATION IN QUARTERLY PRESCRIPTIONS1 21K 26K Q2'24 Q2'25 +23% 1. IQVIA NPA through June 2025. 2. IQVIA Xponent through June 2025; approximate quarterly prescriber counts. MARKET SHARE IN BR
Slide 11: Investing in Jornay PM to Drive Additional Momentum
11 Investing in Jornay PM to Drive Additional Momentum Increase Awareness and Adoption with Expanded Set of Prescribers • Expanded ADHD sales force to ~180 sales reps deployed to cover full market opportunity • Leveraging non-personal promotion to increase awareness and use of Jornay PM Raise Caregi
Slide 12: Maximize and Enhance Durability of Responsible Pain Management Portfolio
12 Well Positioned to Maximize and Enhance Durability of Responsible Pain Management Portfolio 1. This financial data was provided by Collegium in its press release on Form 8-K and Quarterly Report on Form 10-Q filed with the SEC on August 7, 2025. 2. ATU (Awareness, Trial, & Usage) Market Research
Slide 13: Financial Highlights
Financial Highlights Colleen Tupper Executive Vice President & Chief Financial Officer
Slide 14: Q2'25 Financial Highlights
$96.0M $105.1M Q2'24 Q2'25 Q2’25 Financial Highlights1 Record Product Revenues, Net $145.3M $188.0M Q2'24 Q2'25 +29% Adjusted Operating Expenses2 $30.3M $61.9M Q2'24 Q2'25 +104% Adjusted EBITDA2 +9% 14 1. This financial data was provided by Collegium in its press release on Form 8-K and Quarterly Re
Slide 15: Raised 2025 Financial Guidance
Raised 2025 Financial Guidance: Strong Top-and Bottom-Line Growth 1. Represents a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” on slide 2. 2. This financial data was provided by Collegium in its press release on Form 8-K filed with the SEC on August 7, 2025. 3. This financial d
Slide 16: Disciplined Capital Deployment
Disciplined Capital Deployment 16 1. This financial data was provided by Collegium in its Quarterly Report on Form 10-Q filed with the SEC on August 7, 2025, and Annual Reports on Form 10-K filed with the SEC on February 22, 2024, and February 27, 2025. 2. Adjusted EBITDA is a non-GAAP financial mea
Slide 17: Closing Remarks
Closing Remarks Vikram Karnani President & Chief Executive Officer
Slide 18: Collegium's Next Phase of Growth
Collegium’s Next Phase of Growth 18 Growing Revenue CREATING VALUE FOR SHAREHOLDERS Increasing Profitability Generating Strong Cash Flows Strategically Deploying Capital Business Development
Slide 19: Healthier people. Stronger communities.
19 Healthier people. Stronger communities. Building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.
Slide 20: Non-GAAP Reconciliations
Non-GAAP Reconciliations
Slide 21: Reconciliation of GAAP Net Income to Adjusted EBITDA
21 Reconciliation of GAAP Net Income to Adjusted EBITDA (in thousands, unaudited) GAAP net income $ 11,983 $ 19,606 $ 14,400 $ 47,319 Adjustments: Interest expense 20,463 15,587 41,253 32,926 Interest income (2,383) (4,397) (4,608) (8,884) Loss on extinguishment of debt — 7,184 — 7,184 Provision for
Slide 22: Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses
22 Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses (in thousands, unaudited) GAAP operating expenses $ 73,279 $ 43,335 $ 148,916 $ 85,317 Adjustments: Stock-based compensation 10,818 10,012 22,342 17,487 Executive transition expense — 3,051 1,397 3,051 Acquisition related ex
Slide 23: Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted EPS
23 Reconciliation of GAAP Net Income to Adjusted Net Income and Adjusted Earnings Per Share (in thousands, except share and per share amounts, unaudited) 1. The income tax effect of the adjustments was calculated by applying our blended federal and state statutory rate to the items that have a tax e
Collegium Pharmaceutical — Q2 2025 Earnings Presentation on 6ix